Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

Medics4RareDiseases

Medics4RareDiseases
Web Address: Medics4RareDiseases

Medics4RareDiseases (or M4RD) is UK charity with a mission to build a healthcare workforce that is trained and supported to meet the needs of those living with rare conditions, so that patients feel listened to, believed and involved. The charity has a vision for a world in which no one faces inequality in healthcare based on the rarity of their condition.

M4RD works closely with patients and rare disease advocates, and alongside universities, foundation schools, royal colleges, hospitals and trusts. The charity creates patient-centred, dedicated rare disease education for healthcare professionals. This can be provided in-person or accessed online at https://learn.m4rd.org. M4RD also works with governmental bodies and outside organisations to advocate for the inclusion of dedicated Rare Disease training within the medical education curricula.

M4RD started out as a medical student society Barts and The London School of Medicine and Dentistry, QMUL in 2011. It was registered as a charity in 2018 and made major contributions to the development of The UK Rare Diseases Framework published by the Department of Health and Social Care. M4RD continues to advise on implementation and development of policy for rare disease.

Further Resources

Close Popup